Novo Nordisk Announces Two Major Licensing Deals Worth Nearly $4 Billion
On September 24 and 29, Novo Nordisk (NVO) announced two significant licensing deals aimed at strengthening its position in the growing weight-loss market. The first deal involves acquiring Nanexa’s PharmaShell drug-delivery technology for up to €1.165 billion ($1.32 billion), which could enable longer dosing intervals for Novo's obesity and diabetes treatments, potentially as infrequent as quarterly. The second deal is with Hengrui Pharma (China) for the investigational oral anti-obesity drug HRS-1596, a dual GLP-1/GIP agonist similar to Eli Lilly’s Zepbound, which could be taken weekly instead of daily like Novo's current oral Wegovy. These deals highlight Novo’s strategy to offer more convenient treatment options and differentiate itself from competitors in the obesity drug space. The potential for these new therapies is significant given the expanding market demand for effective weight-loss treatments. If successful, they could enhance patient adherence due to less frequent dosing schedules while maintaining or improving efficacy compared to existing products like Wegovy. Novo’s recent clinical successes with zenagamtide and UBT251 further support its strong pipeline in metabolic diseases.
Topics: licensing deals Novo Nordisk obesity drugs pharmaceuticals